AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation.

Area of Science:

• Neuroscience
• Endocrinology
• Pathology

Background:

• Sporadic Alzheimer disease (AD) pathogenesis is complex and linked to aging.
• Diabetes is a known risk factor for AD, with proposed shared mechanisms.
• Hyperglycemia in diabetes promotes advanced glycation end products (AGEs), which interact with the receptor for AGEs (RAGE), potentially contributing to AD pathology.

Purpose of the Study:

• To investigate the functional link between diabetes and AD by examining the effect of specific AGEs on BACE1 expression.
• To explore the role of the AGEs/RAGE axis in upregulating BACE1, the enzyme responsible for amyloid-beta production.

Main Methods:

• In vivo studies using streptozotocin-treated rats.
• In vitro studies using differentiated neuroblastoma cells.
• Analysis of pentosidine and glyceraldehyde-derived pyridinium (GLAP) effects on BACE1 expression and NF-κB activation.

Main Results:

• Pentosidine and GLAP were found to upregulate BACE1 expression.
• This upregulation occurred through RAGE binding and subsequent NF-κB activation.
• Elevated levels of pentosidine and GLAP were observed in the brains of sporadic AD patients.

Conclusions:

• Activation of the AGEs/RAGE axis upregulates BACE1, the key enzyme in amyloid-beta production.
• This provides a pathological link between diabetes mellitus and Alzheimer disease.
• Targeting the AGEs/RAGE pathway may offer therapeutic strategies for both conditions.